Recent announcements

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2022
May
Press Release
5 May
2022

POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial

Clinical doses continue to be manufactured and shipped from the Company’s Indianapolis, Indiana facility

2022
April
Press Release
26 Apr
2022

First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial

POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe. Sites initiated in France, Sweden, Netherlands, and the UK, with randomization in each expected this summer.

2022
April
Press Release
11 Apr
2022

POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting

POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for summer 2022

2022
March
Press Release
25 Mar
2022

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial. Randomization phase of SPLASH trial ongoing, top line data expected mid-2023. Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022. Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses of PNT2002 to support the SPLASH trial – view the facility online at manufacturing.pointbiopharma.com.

2022
March
Press Release
22 Mar
2022

POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption

POINT’s industry-leading radioisotope supply chain enabled company to avoid delays

2022
March
Press Release
15 Mar
2022

POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022

Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals. Register online at https://hub.pointbiopharma.com/dosimetry

2022
February
Press Release
25 Feb
2022

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied Red marrow dosimetry was well below critical thresholds, enabling a potential opportunity for combination therapy

2022
February
Press Release
14 Feb
2022

POINT Biopharma Provides Early-Stage Program Updates

Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022. Initiated IND-enabling studies for next-generation actinium-225 radiolabeled PSMA targeted program, PNT2001, to support an IND/CTA filing expected H1 2023.